/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
With a market cap of $13.3 billion, Incyte Corporation (INCY) is a global biopharmaceutical company focused on discovering, developing, and commercializing therapies in oncology, inflammation, and autoimmunity. The Wilmington, Delaware-based company has over 2,600 employees and a manufacturing and R&D footprint across North America, Europe, and Asia.
Companies valued at $10 billion or more are generally labelled as “large-cap” stocks, and Incyte fits this criterion perfectly. Its leadership stems from its strong portfolio of high-demand specialty drugs, notably Jakafi and Opzelura, which serve as key revenue drivers in the oncology and dermatology markets. Its robust research and development capabilities, with a diverse and advancing pipeline targeting cancer, inflammation, and autoimmune diseases, position it for long-term innovation.
